Showing papers by "Michel Farnier published in 2011"

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

Abstract: Fibrates have been reported to cause paradoxical decreases in HDL-C in certain patients. This post-hoc analysis explored the frequency/magnitude of HDL-C reductions in a pooled database of mixed dyslipidemic patients (LDL-C:3.4-5.7 mmol/L;TG:1.7-5.7 mmol/L) receiving placebo (PBO), fenofibrate (FENO), ezetimibe plus FENO (EZE+FENO), or EZE/simvastatin plus FENO (EZE/SIMVA+FENO) for 12 weeks. PBO-treated patients had the highest incidence of HDL-C reductions from baseline (45%) compared with patients taking FENO (14%), EZE+FENO (9%), or EZE/SIMVA+FENO (9%). Reductions <30% reflected natural variability since the largest reduction in HDL-C approached 30% in the PBO group. Only 3 patients exhibited HDL-C reductions ≥30% (i.e., 2 patients in the FENO group and 1 in the EZE+FENO group). There were no differences in demographic/biochemical characteristics between patients with and without HDL-C reductions. The incidence of paradoxical HDL-C reductions was low in mixed dyslipidemic patients receiving FENO alone or combined with EZE or EZE/SIMVA. Clinicaltrials.gov: NCT00092560 and NCT00092573

Recommandations pour la prise en charge des hypercholestérolémies de l'enfant.

Abstract: Un risque eleve d'atherosclerose precoce et de complications cardiovasculaire prematurees est present chez des enfants atteints de certaines hypercholesterolemies. Ces hypercholesterolemies sont les hypercholesterolemies monogeniques transmises sur le mode autosomique dominant, et principalement l'hypercholesterolemie familiale causee par une anomalie du gene du recepteur du LDL. Cet article, elabore conjointement par la Nouvelle Societe francaise d'atherosclerose et le comite de nutrition de la societe francaise de pediatrie propose des recommandations pour le depistage et la prise en charge de l'hypercholesterolemie chez l'enfant. La conduite pratique permettant reperer les hypercholesterolemies hereditaires a risque eleve est precisee, les principes et les modalites du traitement dietetique sont detailles de meme que les indications, les modalites et la surveillance du traitement medicamenteux.

Efficacy of Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity

Abstract: Introduction: This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in high-risk hypercholesterolemic patients with/without obesity. Methods: Patients (n=618) at high-risk for coronary heart disease with elevated low-density lipoprotein cholesterol (LDL-C) ≥2.59 and ≤4.92 mmol/L, while on a statin, entered a 6-week open-label stabilization/screening period during which they continued on the same statin. Patients were then randomized 1:1 to double-blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks. Patients were classified as non-obese (n=437) or obese (n=180) based on body mass index 0.050 for all). Conclusions: In this post-hoc analysis of high-risk patients with elevated LDL-C, despite prior use of statin therapy, switching to EZE/SIMVA 10/20 mg versus ROSUVA 10 mg provided superior reductions in LDL-C, TC, and non-HDL-C in obese and non-obese patients.